Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 3
2005 4
2006 6
2007 3
2008 8
2009 3
2010 5
2011 6
2012 9
2013 9
2014 9
2015 4
2016 2
2017 3
2018 2
2019 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

73 results
Results by year
Filters applied: . Clear all
Page 1
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Llovet JM, et al. Among authors: sola r. Lancet. 2002 May 18;359(9319):1734-9. doi: 10.1016/S0140-6736(02)08649-X. Lancet. 2002. PMID: 12049862 Clinical Trial.
[Hepatitis C treatment in special patient groups].
Berenguer M, Jorquera F, Ángel Serra M, Sola R, Castellano G. Berenguer M, et al. Among authors: sola r. Gastroenterol Hepatol. 2014 Jul;37 Suppl 1:23-36. doi: 10.1016/S0210-5705(15)30004-2. Gastroenterol Hepatol. 2014. PMID: 25907435 Review. Spanish.
Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
González-Colominas E, Londoño MC, Morillas RM, Torras X, Mojal S, Lens S, López D, Gallego A, Mariño Z, Ardèvol M, Pagès N, Solà R, Carrión JA. González-Colominas E, et al. Among authors: sola r. J Gastroenterol Hepatol. 2018 May;33(5):1100-1107. doi: 10.1111/jgh.14014. Epub 2018 Feb 12. J Gastroenterol Hepatol. 2018. PMID: 28994141
73 results